Emerging therapies for the treatment of hepatitis C
- Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon-α monotherapy in 1992 to the approval of telaprevir- and boceprevir-based triple therapies with pegylated interferon-α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. Significant further improvements are on the horizon, which may well cure virtually all hepatitis C patients with an all-oral, interferon-free regimen in the very near future. These exciting developments are reviewed in the present article.
Author: | Christian LangeGND, Ira M. Jacobson, Charles M. Rice, Stefan ZeuzemORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-347134 |
DOI: | https://doi.org/10.1002/emmm.201303131 |
ISSN: | 1715-4684 |
ISSN: | 1757-4676 |
Parent Title (English): | EMBO molecular medicine |
Publisher: | Wiley-VCH |
Place of publication: | Weinheim |
Document Type: | Article |
Language: | English |
Year of Completion: | 2013 |
Date of first Publication: | 2013/09/16 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Release Date: | 2014/07/25 |
Tag: | NS3-4A protease inhibitor; NS5B polymerase inhibitor; directly acting antiviral agents; hepatitis C virus; interferon-free |
Volume: | 6 |
Issue: | 1 |
Page Number: | 12 |
First Page: | 4 |
Last Page: | 15 |
Note: | © 2013 The Authors. This is an open access article under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/ , which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
HeBIS-PPN: | 366010662 |
Institutes: | Medizin / Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Licence (German): | Creative Commons - Namensnennung 3.0 |